MTOR and angiomyolipoma: Studies have consistently reported that mTOR inhibitors are associated with controlling the growth of angiomyolipoma, reducing both its size and the risk of bleeding and the need for surgical intervention, while preserving renal function with a relatively low incidence of serious adverse effects32–47,48.